Beijing Centergate Technologies (000931.SZ) subsidiary receives approval for BDB tablet drug clinical trial
Beijing Centergate Technologies (000931.SZ) announced that its subsidiary Shandong Huasu Pharmaceutical Co., Ltd. recently received the Drug Clinical Trial Approval Notice for BDB tablets issued by the National Medical Products Administration. The drug is intended for the treatment of essential hypertension and is a new fixed-dose combination containing known active ingredients that has not been marketed domestically or internationally. Its individual components have demonstrated efficacy and safety in clinical practice, and their combined use is recommended by clinical guidelines.
Beijing Centergate Technologies (000931.SZ) announced that its subsidiary Shandong Huasu Pharmaceutical Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" for BDB tablets issued by the National Medical Products Administration. The drug is intended for the treatment of essential hypertension and is a new fixed-dose combination containing known active ingredients, and has not been marketed either domestically or abroad. Its individual components have demonstrated efficacy and safety in clinical practice, and their combined use is recommended by clinical guidelines.
Related Articles
US Stock Market Move | Nasdaq Composite Index extends gains to 1.2%; semiconductor concept stocks rise
AI compute expansion opens up growth space! Bernstein raises SpaceX (SPCX.US) price target to $268; Morgan Stanley maintains "Overweight" rating.
US Stock Market Move | Morgan Stanley names NVIDIA Corporation (NVDA.US) as top semiconductor pick amid the "power shortage bottleneck," shares rise nearly 3%
US Stock Market Move | Nasdaq Composite Index extends gains to 1.2%; semiconductor concept stocks rise
AI compute expansion opens up growth space! Bernstein raises SpaceX (SPCX.US) price target to $268; Morgan Stanley maintains "Overweight" rating.
US Stock Market Move | Morgan Stanley names NVIDIA Corporation (NVDA.US) as top semiconductor pick amid the "power shortage bottleneck," shares rise nearly 3%
